Zolmitriptan
زولمیتریپتان
🧠 Nervous SystemTriptan (5-HT1B/1D agonist)
Market / country: 🇺🇸 USA
Zomig (US)
🧮 Dose calculator
Acute migraine attack · Regimen source: FDA Zolmitriptan · 2.1
- • Repeat after 2 h if not resolved or recurs; max 10 mg in 24 h. Moderate/severe hepatic impairment: 1.25 mg (severe max 5 mg/day). With cimetidine max 2.5 mg single and 5 mg/day. FDA Zolmitriptan · 2.1FDA Zolmitriptan · 2.3FDA Zolmitriptan · 2.4
Enter age (weight is optional for this regimen).
🛡️ Safety & information
Contraindications
- ⛔ Ischaemic coronary disease or coronary vasospasm (Prinzmetal); WPW or accessory-pathway arrhythmias; history of stroke, TIA or hemiplegic/basilar migraine; peripheral vascular disease; ischaemic bowel disease; uncontrolled hypertension; another triptan or ergot within 24 h; hypersensitivity. FDA Zolmitriptan · 4
- ⛔ MAO-A inhibitor concomitantly or within 2 weeks. FDA Zolmitriptan · 4
Warnings
- • Myocardial ischaemia and infarction; arrhythmias; chest/throat/jaw tightness; cerebrovascular events; medication-overuse headache; serotonin syndrome; increased blood pressure. FDA Zolmitriptan · 5
Formulations
- 2.5 mg tablet (functionally scored) — tablet 🇺🇸 USA FDA Zolmitriptan · 3
- 5 mg tablet — tablet 🇺🇸 USA FDA Zolmitriptan · 3
👥 Special populations
- 🤰 PregnancyUse with caution
Label states no clear risk or has limited data; use only if needed, under medical advice. FDA Zolmitriptan · 8.1
“Risk Summary There are no adequate data on the developmental risk associated with the use of zolmitriptan in pregnant women.”
- 🤱 BreastfeedingUse with caution
Label: use with caution while breastfeeding; see the label text. FDA Zolmitriptan · 8.2
“Risk Summary There are no data on the presence of zolmitriptan or its metabolites in human milk, the effects on the breastfed infant, or the effects of zolmitriptan and its metabolites on milk production.”
- 👶 ChildrenSafety not established
Label: safety and effectiveness in children have not been established. FDA Zolmitriptan · 8.4
“The safety and effectiveness in pediatric patients have not been established.”
- 👴 Older adultsUse with caution
Label: use with caution in older adults, usually starting at the low end of the dose range. FDA Zolmitriptan · 8.5
“In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy.”
- ⚥ Females & males of reproductive potentialNo data
The source for this drug has no section for this group.
🔗 Reference links
- FDA (approval record)ANDA201779
- DailyMed (FDA label)FDA Zolmitriptan
- MedlinePlus (NIH)ZolmitriptanZolmitriptan Nasal Spray
- WHO ATC/DDDN02CC03
- Darooyab (Iran)Zolmitriptan
🇮🇷 Registered in Iran Darooyab · G-865/Zolmitriptan
Dosage forms with Iranian generic codes, per Darooyab.
- 06840 · ZOLMITRIPTAN 2.5MG TAB · قرص زولمیتریپتان ۲٫۵ میلیگرم
- 18158 · ZOLMITRIPTAN 5MG SPRAY NASAL · اسپری بینی زولمیتریپتان ۵ میلیگرم
- 20387 · ZOLMITRIPTAN 5MG TAB · قرص زولمیتریپتان ۵ میلیگرم
📚 Reference status for this drug
Shows which sources have references recorded for this drug and which do not.
- FDA label (DailyMed)✅ PresentFDA Zolmitriptan · 3FDA Zolmitriptan · 2.1FDA Zolmitriptan · 2.3FDA Zolmitriptan · 2.4FDA Zolmitriptan · 4FDA Zolmitriptan · 5FDA Zolmitriptan · SPL approval / marketing categoryFDA Zolmitriptan · 8.1FDA Zolmitriptan · 8.2FDA Zolmitriptan · 8.4FDA Zolmitriptan · 8.5
- UK SmPC (eMC / MHRA)❌ Not present
- Published guideline❌ Not present
- Licensed reference (medical school)❌ Not present
- Iranian leaflet (IFDA)❌ Not present
- Pharmacy website (secondary, unreliable)✅ PresentDarooyab · G-865/Zolmitriptan
- Clinical review⚠ Unverified